The pilot study sponsored by AdventHealth Translational Research Institute aims to assess the tolerability of glucagon infusion in obese subjects, which could have significant implications for obesity management and metabolic disorders. Given the increasing prevalence of obesity globally, successful outcomes may position glucagon as a viable therapeutic option, potentially competing with existing weight management drugs such as GLP-1 agonists. The study's focus on tolerability is critical, as adverse effects can limit patient adherence and market uptake. The asset's development could attract interest from larger pharmaceutical companies looking to expand their obesity treatment portfolios, particularly if the results indicate a favorable safety profile. However, the competitive landscape includes established therapies, necessitating a robust differentiation strategy.